1. GBS vaccine candidate clears a first key hurdle in HIV-endemic Africa A Ugandan phase 2 trial shows a hexavalent GBS6 vaccine candidate is safe and equally immunogenic in pregnant women with and without HIV, offering...
Summary This GSK-sponsored retrospective cohort study used US Merative MarketScan claims data (2015–2022) covering over 20.6 million adults to compare herpes zoster (HZ) incidence rates in immunocompetent adults aged...